Qureight announced a new Scientific Advisory Board (SAB) focused on pulmonary hypertension (PH) to guide AI imaging model development for clinical trials.
SAB members include global experts:
Marc Humbert (France), Steven Nathan (USA), Oksana Shlobin (USA), Vincent Cottin, Ardeschir Ghofrani (Germany), Joanna Pepke-Zaba (UK), and Luke Howard.
The SAB aims to advance non-invasive assessment of PH disease severity, patient stratification, and treatment response monitoring.
PH involves elevated pulmonary circulation pressure with high unmet treatment needs; current monitoring often requires invasive right heart catheterization.
Dr. Simon Walsh, Qureight's Chief Scientific Officer, highlighted the board's role in addressing gaps in PH trial design.